For research use only. Not for use in humans.

Enoblituzumab (Anti-B7-H3 / CD276)

Synonyms: MGA271 Cat.No.A2626 Purity:99%

Enoblituzumab (Anti-B7-H3 / CD276) is a humanised IgG1κ monoclonal antibody targeting human B7-H3 protein. It can be used in the treatment of medullary thyroid cancer (MTC). MW: 150 KD.

Quality Control

Batch: Purity: 99% Protein concentration: 4.37mg/ml Endotoxin Level: ＜1EU/mg

Specificity

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Enoblituzumab (Anti-B7-H3 / CD276) is a humanised IgG1κ monoclonal antibody targeting human B7-H3 protein. It can be used in the treatment of medullary thyroid cancer (MTC). MW: 150 KD.
References	[1] https://pubmed.ncbi.nlm.nih.gov/34680929/

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	1353485-38-7
Molecular Weight	150
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Sellecks selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.